Q3 Beat and Raised Guidance Overshadowed by Cyber Incident at Quest
DGX sits 39% above its 52-week low of $171.175.
Summary
Quest posted Q3 revenue of about $3.10B, up 10% year over year, with GAAP EPS of $2.78 and adjusted EPS of $3.00, up 15%. It raised FY26 revenue guidance to $12.065–$12.105B and adjusted EPS to $11.25–$11.35, extending the upward revisions from the Q2 report in July. The offsetting item is a disclosed cybersecurity incident: unauthorized access to its Quanum LSM ordering and results system on October 21, 2026, and the stock fell after the disclosure. On the growth side, Quest will offer an individual lab test kit covering 50+ biomarkers through the Apple Health app later this year, agreed to buy select Northeast U.S. external labs and assets, expanded Co-Lab Solutions testing with Corewell Health in Michigan, and added Roche Elecsys pTau217 to its AD-Detect Alzheimer's panel. The guidance raise is the core earnings fact; the cyber incident is the open risk, since the company has not yet quantified the operational or financial impact.
At the time of this announcement, DGX was trading at $238.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.9B. The 52-week trading range was $171.18 to $248.84. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.